What is Precision Biologics?
Precision Biologics is a clinical-stage biotechnology enterprise dedicated to the development of sophisticated therapeutic and diagnostic solutions for oncology. By leveraging proprietary cancer vaccines and targeted antibody drug candidates, the company aims to revolutionize the standard of care by identifying and neutralizing malignant cells while preserving healthy tissue. The firm's core competency lies in its ability to integrate breakthrough biotechnological advancements with rigorous human trial protocols, positioning it as a high-potential player in the precision medicine sector. Its market position is defined by a focus on high-specificity therapeutics that minimize systemic toxicity, a key differentiator in the current biopharmaceutical landscape.
How much funding has Precision Biologics raised?
Precision Biologics has raised a total of $73.1M across 6 funding rounds:
Private Equity
$5.3M
Multiple Rounds
$14.6M
Private Equity
$53.1M
Debt
$150K
Private Equity (2012): $5.3M, investors not publicly disclosed
Private Equity (2013): $3.3M, investors not publicly disclosed
Unspecified (2013): $10.5M, investors not publicly disclosed
Private Equity (2013): $795K, investors not publicly disclosed
Private Equity (2015): $53.1M, investors not publicly disclosed
Debt (2020): $150K with participation from PPP
Key Investors in Precision Biologics
Undisclosed Investor
An institutional backer providing capital to support the long-term clinical development of oncology therapeutics.
PPP
Public-Private Partnership
Private Equity Syndicate
A group of private equity participants focused on high-growth biotechnology ventures with significant clinical potential.
What's next for Precision Biologics?
With the recent infusion of capital, Precision Biologics is well-positioned to scale its clinical development programs and refine its diagnostic platform. The strategic roadmap likely involves the advancement of its lead antibody candidates through late-stage human trials, alongside potential partnerships to enhance its commercialization capabilities. As the company navigates the complexities of the regulatory environment, the focus will remain on validating its proprietary technology in broader patient populations. Investors will be closely monitoring the firm's ability to translate its clinical successes into scalable, market-ready products that offer superior efficacy compared to traditional chemotherapy and radiation modalities. The company's growth trajectory suggests a transition toward becoming a significant contributor to the next generation of oncology care.
See full Precision Biologics company page
